FOLH1 and prostate neoplasm: As examples, SELEX-generated APs against the prostate tumor marker prostate membrane-specific antigen have been used to safely and effectively direct chemotherapeutic drugs to prostate tumor cells [10,11], and epidermal growth factor (EGF)-receptor targeted APs conjugated to a gemcitabine-containing polymer inhibited in vitro proliferation of PDAC cells [12].